Karyopharm Therapeutics(US:KPTI) ZACKSยท2025-07-29 15:01Core Viewpoint - Karyopharm Therapeutics (KPTI) is expected to report a year-over-year decline in earnings and revenues for the quarter ended June 2025, with the consensus outlook indicating a loss of $3.80 per share and revenues of $40.08 million, reflecting a 26.7% and 6.3% decrease respectively [1][3]. Earnings Expectations - The upcoming earnings report could lead to a stock price increase if the actual results exceed expectations, while a miss could result in a decline [2]. - The consensus EPS estimate has been revised 2.21% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that Karyopharm has a positive Earnings ESP of +0.92%, indicating a likelihood of beating the consensus EPS estimate [12]. - The stock currently holds a Zacks Rank of 3, which supports the potential for an earnings beat [12]. Historical Performance - Karyopharm has a history of exceeding consensus EPS estimates, having beaten expectations in the last four quarters [14]. - In the last reported quarter, the company was expected to post a loss of $4.21 per share but actually reported a loss of -$2.77, resulting in a positive surprise of +34.20% [13]. Industry Context - In the Zacks Medical - Drugs industry, Ardelyx (ARDX) is expected to report a loss of $0.13 per share, indicating a significant year-over-year decline of 85.7%, with revenues projected at $84.64 million, up 15.6% from the previous year [18]. - Ardelyx's consensus EPS estimate has been revised 6.3% lower, resulting in a negative Earnings ESP of -6.18%, combined with a Zacks Rank of 4, making it difficult to predict an earnings beat [19].